1,3-二氢-2H-异吲哚-2-甲酰氯 | 3432-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 1,3-二氢-2H-异吲哚-2-甲酰氯
• 英文名称: isoindoline-2-carbonyl chloride
• 英文别名: Isoindolin-2-carbonylchlorid；1,3-dihydro-isoindole-2-carbonyl chloride；2-Isoindolinecarbonyl chloride；1,3-dihydroisoindole-2-carbonyl chloride
• CAS: 3432-58-4
• 化学式: C₉H₈ClNO
• 分子量: 181.622
• InChiKey: ULBYXUAYQUKEEA-UHFFFAOYSA-N

物化性质

• 熔点：
  125-127 °C
• 沸点：
  326.2±32.0 °C(Predicted)
• 密度：
  1.338±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1,3-二氢-2H-异吲哚-2-甲酰氯 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 二氯甲烷 为溶剂， 生成 (1S,4R,6S,14S,18R)-18-(1,3-dihydroisoindole-2-carbonylamino)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid
  参考文献：
  名称：

  Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

  摘要：

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.

  DOI：

  10.1021/jm400164c
• 作为产物：
  描述：

  异吲哚啉 、 3,4-二氢-2(1H)-异喹啉羰基氯化物 生成 1,3-二氢-2H-异吲哚-2-甲酰氯
  参考文献：
  名称：

  Medicaments

  摘要：

  描述了一种正式化合物(I)：其中R1和R2如文本中所定义，并且这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗条件。

  公开号：

  US20110046153A1

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• [EN] INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES<br/>[FR] INGÉNOL-3-ACYLATES III ET INGÉNOL-3-CARBAMATES
  申请人：LEO PHARMA AS

  公开号：WO2012083953A1

  公开（公告）日：2012-06-28

  The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is -NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

  该发明涉及一般式I的化合物，其中R为杂环芳基，可选择地由R7取代；或R为杂环烷基或杂环烯基，可选择地由R8取代；或R为X，其中X为-NR11R12；以及其在治疗中的药物可接受的盐、水合物或溶剂合物，用于单独使用或与一个或多个其他药用活性化合物结合在一起，用于预防、治疗或改善对中性粒细胞氧化爆发的刺激响应、对角质细胞IL-8释放的刺激响应或对坏死诱导的刺激响应的疾病或症状。
• [EN] MEDICAMENTS<br/>[FR] MÉDICAMENTS
  申请人：MOTAC NEUROSCIENCE LTD

  公开号：WO2009056805A1

  公开（公告）日：2009-05-07

  A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

  描述了一种化合物的化学式(I)：其中R1和R2如文本中定义的那样，这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗状况。
• Remote Tris(pentafluorophenyl)borane-Assisted Chiral Phosphoric Acid Catalysts for the Enantioselective Diels–Alder Reaction
  作者：Kazuaki Ishihara、Manabu Hatano、Hideyuki Ishihara、Yuta Goto

  DOI：10.1055/s-0035-1560369

  日期：——

  supramolecular phosphoric acid catalysts were developed for the model Diels–Alder reaction of α-substituted acroleins with cyclopentadiene. Two remotely coordinated tris(pentafluorophenyl)boranes should help to increase the Bronsted acidity of the active center in the supramolecular catalyst and create effective bulkiness for the chiral cavity. The prepared supramolecular catalysts acted as not only conjugated

  三（五氟苯基）硼烷辅助的手性超分子磷酸催化剂被开发用于α-取代丙烯醛与环戊二烯的模型 Diels-Alder 反应。两个远程协调的三（五氟苯基）硼烷应该有助于增加超分子催化剂中活性中心的布朗斯台德酸度，并为手性空腔创造有效的体积。制备的超分子催化剂不仅可以作为共轭布朗斯台德酸-布朗斯台德碱催化剂，而且还可以作为双功能路易斯酸-布朗斯台德碱催化剂，添加中心非手性路易斯酸源如儿茶酚硼烷。
• MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
  申请人：BLATT LAWRENCE M.

  公开号：US20090286843A1

  公开（公告）日：2009-11-19

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合物在内的组合物。该实施例还提供了治疗方法，包括治疗黄热病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述化合物或组合物的有效量。